Thalidomide-CH2CONH-C3-COOH

Background Introduction

Thalidomide-CH2CONH-C3-COOH is a small-molecule E3 ligase ligand-linker conjugate designed for use in targeted protein degradation technologies, such as PROTACs (Proteolysis Targeting Chimeras). Based on thalidomide, a well-characterized ligand for the Cereblon (CRBN) E3 ubiquitin ligase, this molecule incorporates a specialized linker and functional group (carboxylic acid) for easy conjugation. The thalidomide-core grants selective CRBN engagement, essential for designing next-generation protein degraders.

Mechanism

The mechanism of Thalidomide-CH2CONH-C3-COOH centers around targeted ubiquitination. Upon incorporation into a bifunctional molecule, the thalidomide moiety recruits the CRBN E3 ubiquitin ligase complex. The incorporated linker (CH2CONH-C3) provides optimal spatial separation between the E3 ligase and the target protein ligand, minimizing steric hindrance. The carboxylic acid group at the terminus allows for efficient chemical conjugation with various target protein binding warheads. This design enables the subsequent assembly of PROTACs, which facilitate the transfer of ubiquitin tags to the target protein, marking it for rapid degradation by the proteasome.

Applications

Thalidomide-CH2CONH-C3-COOH is widely used in the development of PROTACs and molecular glues that exploit the CRBN E3 ligase pathway. It serves as a modular building block for synthesizing customized protein degraders targeting disease-related proteins, such as kinases, transcription factors, or oncoproteins. Researchers leverage this conjugate to expand their chemical toolbox for drug discovery, mechanistic studies, and the development of next-generation therapeutics for cancer, neurodegeneration, and autoimmune diseases. With its versatile linker and high ligase affinity, Thalidomide-CH2CONH-C3-COOH facilitates rapid construction of PROTAC libraries, streamlining structure-activity relationship (SAR) studies and accelerating the optimization of targeted protein degraders.

• Carboxylic acid functionality enables versatile conjugation to various warheads and linkers, enhancing PROTAC design flexibility.
• Optimized for effective recruitment of CRBN E3 ligase, facilitating efficient targeted protein degradation in PROTAC applications.

Thalidomide-CH2CONH-C3-COOH is an E3 Ligase Ligand-Linker Conjugate designed for use in PROTACs, offering a versatile approach to targeted protein degradation. This conjugate facilitates the recruitment of E3 ligases to specific protein targets, enhancing the selectivity and efficiency of protein degradation. The following provides a detailed description of this molecule.

Linker: The linker in Thalidomide-CH2CONH-C3-COOH is a short, three-carbon chain, providing moderate flexibility to accommodate diverse spatial orientations. Its non-cleavable nature ensures stable conjugation between the ligand and the target protein, making it suitable for sustained interaction in cellular environments.

Ligand: The ligand component is derived from thalidomide, a well-characterized small molecule known for its high affinity to the cereblon E3 ligase. Its structural characteristics include a phthalimide ring, which is critical for its binding efficiency and selectivity, facilitating effective recruitment of the E3 ligase.

Reactive Site: The reactive site of this molecule is the terminal carboxylic acid group, which can form stable amide bonds with primary amine groups on target protein ligands. Recommended reaction types for coupling include amide bond formation through carbodiimide-mediated reactions or using activated esters.

Recommended Target Protein Ligand: The compatible warhead for this conjugate is typically an amine-containing small molecule or peptide, which can form a stable linkage with the carboxylic acid group. This provides the advantage of creating a robust and irreversible connection, ensuring effective degradation of target proteins in experimental settings. Applications include the study of protein function and the validation of therapeutic targets.